CDKN2A and cancer: The discovery of cancer-associated hypermethylation of the gene cyclin-dependent kinase inhibitor 2A (CDKN2A), coding for a CDK inhibitor protein also known as p16, marked one of the earliest demonstrations of a tumor-driving role of DNA hypermethylation [47].